Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05119387 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genetic Study of Amyotrophic Lateral Sclerosis in Norway

Study acronym: GAIN
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv4
  2. Enrollment target: 500 to 1200v3 Show 6 more changesShow less
    • Primary completion date: Jul 31, 2023 to Dec 31, 2030
    • Primary endpoints: 2 to 3
    • Trial status: Enrolling by Invitation to Recruiting
    • Study completion date: Dec 31, 2030 to Dec 31, 2035
    • Site details revised at 17 of 17 sites
    • Eligibility criteria expanded, about 5 words
  3. Primary completion date: Jul 30, 2022 to Jul 31, 2023
    • Study completion date: Dec 31, 2025 to Dec 31, 2030
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sykehuset Telemark
12 trials monitored
See all monitored trials
ALS
398 trials monitored
See 21 trials at risk
The purpose of this study is to explore the genetic causes relevant for ALS development in Norway.
Trial Details
NCT Number NCT05119387
Lead Sponsor Sykehuset Telemark
Collaborators: ALS Norge, Helse Sor-Ost
Conditions
(from sponsor)		 Amyotrophic Lateral Sclerosis
Related terms Amyotrophic Lateral Sclerosis
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov